Individual interventions

Matthew J. Mimiaga, Sari L. Reisner, Laura Reilly, Nafisseh Soroudi, Steven Safren

Research output: Chapter in Book/Report/Conference proceedingChapter

4 Citations (Scopus)

Abstract

This chapter describes individual interventions for HIV prevention from the perspective of a three-stage model of behavioral therapy development. This is highly applicable to individual interventions for HIV prevention, due to the sequential approach to designing and refining culturally appropriate interventions. The chapter reviews the most common theoretical models used to design behavioral interventions, and how successful they have been when applied to individual interventions for HIV risk behaviors. In biomedical intervention development, clinical researchers use the regulatory standards set forth by the Food and Drug Administration (FDA) for pharmacotherapy and other biomedical clinical intervention trials. The AIDS risk reduction model (ARRM) is one of several stages of change models that posit behavior change to be a process in which individuals move from one step to the next as a result of a given stimulus. The ARRM combines aspects of the health belief model, the diffusion of innovation theory, and social cognitive theory. In the ARRM, an individual must pass through three stages: behavior labeling, commitment to change, and taking action. Consequently, interventions using this model focus on conducting an individual risk assessment, influencing the decision to reduce risk through perceptions of enjoyment or self-efficacy, and assisting the individual with support to enact the change.

Original languageEnglish (US)
Title of host publicationHIV Prevention
PublisherElsevier Inc.
Pages203-239
Number of pages37
ISBN (Print)9780123742353
DOIs
StatePublished - 2009
Externally publishedYes

Fingerprint

Risk Reduction Behavior
Acquired Immunodeficiency Syndrome
HIV
Diffusion of Innovation
Self Efficacy
United States Food and Drug Administration
Risk-Taking
Theoretical Models
Research Personnel
Clinical Trials
Drug Therapy
Health
Drug therapy
Risk assessment
Labeling
Refining
Innovation
Therapeutics

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Mimiaga, M. J., Reisner, S. L., Reilly, L., Soroudi, N., & Safren, S. (2009). Individual interventions. In HIV Prevention (pp. 203-239). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-374235-3.00008-X

Individual interventions. / Mimiaga, Matthew J.; Reisner, Sari L.; Reilly, Laura; Soroudi, Nafisseh; Safren, Steven.

HIV Prevention. Elsevier Inc., 2009. p. 203-239.

Research output: Chapter in Book/Report/Conference proceedingChapter

Mimiaga, MJ, Reisner, SL, Reilly, L, Soroudi, N & Safren, S 2009, Individual interventions. in HIV Prevention. Elsevier Inc., pp. 203-239. https://doi.org/10.1016/B978-0-12-374235-3.00008-X
Mimiaga MJ, Reisner SL, Reilly L, Soroudi N, Safren S. Individual interventions. In HIV Prevention. Elsevier Inc. 2009. p. 203-239 https://doi.org/10.1016/B978-0-12-374235-3.00008-X
Mimiaga, Matthew J. ; Reisner, Sari L. ; Reilly, Laura ; Soroudi, Nafisseh ; Safren, Steven. / Individual interventions. HIV Prevention. Elsevier Inc., 2009. pp. 203-239
@inbook{076f6f6398184ddc8a853b3da171df6a,
title = "Individual interventions",
abstract = "This chapter describes individual interventions for HIV prevention from the perspective of a three-stage model of behavioral therapy development. This is highly applicable to individual interventions for HIV prevention, due to the sequential approach to designing and refining culturally appropriate interventions. The chapter reviews the most common theoretical models used to design behavioral interventions, and how successful they have been when applied to individual interventions for HIV risk behaviors. In biomedical intervention development, clinical researchers use the regulatory standards set forth by the Food and Drug Administration (FDA) for pharmacotherapy and other biomedical clinical intervention trials. The AIDS risk reduction model (ARRM) is one of several stages of change models that posit behavior change to be a process in which individuals move from one step to the next as a result of a given stimulus. The ARRM combines aspects of the health belief model, the diffusion of innovation theory, and social cognitive theory. In the ARRM, an individual must pass through three stages: behavior labeling, commitment to change, and taking action. Consequently, interventions using this model focus on conducting an individual risk assessment, influencing the decision to reduce risk through perceptions of enjoyment or self-efficacy, and assisting the individual with support to enact the change.",
author = "Mimiaga, {Matthew J.} and Reisner, {Sari L.} and Laura Reilly and Nafisseh Soroudi and Steven Safren",
year = "2009",
doi = "10.1016/B978-0-12-374235-3.00008-X",
language = "English (US)",
isbn = "9780123742353",
pages = "203--239",
booktitle = "HIV Prevention",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Individual interventions

AU - Mimiaga, Matthew J.

AU - Reisner, Sari L.

AU - Reilly, Laura

AU - Soroudi, Nafisseh

AU - Safren, Steven

PY - 2009

Y1 - 2009

N2 - This chapter describes individual interventions for HIV prevention from the perspective of a three-stage model of behavioral therapy development. This is highly applicable to individual interventions for HIV prevention, due to the sequential approach to designing and refining culturally appropriate interventions. The chapter reviews the most common theoretical models used to design behavioral interventions, and how successful they have been when applied to individual interventions for HIV risk behaviors. In biomedical intervention development, clinical researchers use the regulatory standards set forth by the Food and Drug Administration (FDA) for pharmacotherapy and other biomedical clinical intervention trials. The AIDS risk reduction model (ARRM) is one of several stages of change models that posit behavior change to be a process in which individuals move from one step to the next as a result of a given stimulus. The ARRM combines aspects of the health belief model, the diffusion of innovation theory, and social cognitive theory. In the ARRM, an individual must pass through three stages: behavior labeling, commitment to change, and taking action. Consequently, interventions using this model focus on conducting an individual risk assessment, influencing the decision to reduce risk through perceptions of enjoyment or self-efficacy, and assisting the individual with support to enact the change.

AB - This chapter describes individual interventions for HIV prevention from the perspective of a three-stage model of behavioral therapy development. This is highly applicable to individual interventions for HIV prevention, due to the sequential approach to designing and refining culturally appropriate interventions. The chapter reviews the most common theoretical models used to design behavioral interventions, and how successful they have been when applied to individual interventions for HIV risk behaviors. In biomedical intervention development, clinical researchers use the regulatory standards set forth by the Food and Drug Administration (FDA) for pharmacotherapy and other biomedical clinical intervention trials. The AIDS risk reduction model (ARRM) is one of several stages of change models that posit behavior change to be a process in which individuals move from one step to the next as a result of a given stimulus. The ARRM combines aspects of the health belief model, the diffusion of innovation theory, and social cognitive theory. In the ARRM, an individual must pass through three stages: behavior labeling, commitment to change, and taking action. Consequently, interventions using this model focus on conducting an individual risk assessment, influencing the decision to reduce risk through perceptions of enjoyment or self-efficacy, and assisting the individual with support to enact the change.

UR - http://www.scopus.com/inward/record.url?scp=78649365537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649365537&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-374235-3.00008-X

DO - 10.1016/B978-0-12-374235-3.00008-X

M3 - Chapter

SN - 9780123742353

SP - 203

EP - 239

BT - HIV Prevention

PB - Elsevier Inc.

ER -